Determinants of ligand selectivity at the kappa-receptor based on the structure of the orphanin FQ receptor.
It is unclear how opioid selectivity and activation are regulated within the receptor core. In previous studies, the OFQ receptor was converted into a functional opioid receptor by mutating five amino acids at three sites to the corresponding residues conserved across the mu-, kappa-, and delta-opioid receptors, suggesting that these sites comprise an opioid binding pocket. To examine this hypothesis, the present study examines whether these conserved residues represent an opioid binding pocket in the context of the opioid receptors, i.e., does their removal from opioid receptors destroy opioid ligand binding? The reciprocal mutations K227A (transmembrane [TM]5), IHI290-292VQV (TM6), and I316T (TM7) were evaluated in the kappa-opioid receptor. In terms of alkaloid binding, there were no changes in affinity for mutants K227A and IHI290-292VQV. At mutant I316T, antagonist binding was unaltered, but there was a trend toward slightly decreased agonist affinity. In contrast, the binding of peptides had a more complex pattern. Again, K227A and IHI290-292VQV did not decrease the binding affinity of dynorphin-related peptides. Mutant I316T had 10- to 20-fold decreased affinity for dynorphin-related peptides, suggesting that I316 is part of a critical dynorphin recognition site. In response to alkaloid stimulation, I316T activated more G-protein(s) than wild type, and similar levels were observed in response to dynorphin stimulation. Overall, these results suggest that ligands are capable of achieving high-affinity binding through interaction with multiple sites/conformations of the receptor. These different modes of interaction have different down-stream results in terms of receptor activation and signal transduction.
Owens
Constance E
CE
Mental Health Research Institute, Department of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA. ceowens@umich.edu
Akil
Huda
H
D000470:Alkaloids / Q000494:pharmacology; D000595:Amino Acid Sequence; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D019556:COS Cells; D017124:Conserved Sequence; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D000882:Haplorhini; D007700:Kinetics; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed / Q000235:genetics; D009154:Mutation / Q000235:genetics; D011869:Radioligand Assay; D051381:Rats; D011957:Receptors, Opioid / Q000737:chemistry* / Q000187:drug effects* / Q000235:genetics; D017473:Receptors, Opioid, kappa / Q000737:chemistry* / Q000187:drug effects* / Q000235:genetics; D000094942:Nociceptin Receptor
D000470:Alkaloids; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D000094942:Nociceptin Receptor